Metabolite-intermediate complexation and inhibition of microsomal CYP3A in rat liver by diltiazem

References

• ABERNETHY, D. R. and MONTAMAT, S. C., 1987, Acute and chronic studies of diltiazem in elderly versus young hypertensive patients. American Journal of Cardiology, 60, 1161–1201.
   Google Scholar
• BARTOWSKI, R. R., GOLDBERG, M. E., LARUANI, G. E. and BOERNER, T., 1989, Inhibition of alfentanil metabolism by erythromycin. Clinical Pharmacology and Therapeutics, 46, 99–102.
   Google Scholar
• BENSOUSSAN C,. DELAFORGE, M. and MANSUY, D., 1995, Particular ability of cytochromes P450 3A to form inhibitory CYP-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochemical Pharmacology, 49, 591–602.
   PubMed Web of Science ®Google Scholar
• BUTLER, A. M. and MURRAY, M., 1993, Inhibition and inactivation of constitutive cytochromes P450 in rat liver by parathion. Molecular Pharmacology, 43, 902–908.
   PubMed Web of Science ®Google Scholar
• DAYER, P., DESMEULES, J. and STRIBERNI, R., 1992, In vitro forecasting of drugs that may interfere with codeine bioactivation. European Journal of Drug Metabolism and Pharmacokinetics, 17, 115–120.
   Google Scholar
• DELAFORGE M., JAOUEN, M. and MANSUY, D., 1983 Dual effects of macrolide antibiotics on rat liver cytochrome P-450. Induction and formation of metabolite-complexes: A structure-activity relationship. Biochemical Pharmacology, 32, 2309–2318.
   PubMed Web of Science ®Google Scholar
• GILLAM, E. M. J., Guo, Z., UENG, Y.-F., YAMAZAKI, H., COCK, I., REILLY, P. E. B., HOOPER, W. D. and GUENGERICH, F. P., 1995, Expression of cytochrome P450 3A5 in EscherichM coli: Effects of 5' modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Archives of Biochemistry and Biophysics, 317, 374–384.
   Google Scholar
• HASSEL, D. and UTT, J. K., 1985, Suspected interaction: warfarin and erythromycin. Southern Medical Journal, 78, 1015–1016.
   Google Scholar
• HOGLUND, P. and NILSSON, L. G., 1989, Pharmacokinetics of diltiazem and its metabolite after single and multiple dosing in healthy volunteers. Therapeutic Drug Monitoring, 11, 558–566.
   PubMed Web of Science ®Google Scholar
• LAEMMLI, U. K., 1971, Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature, 227, 680–685.
   Web of Science ®Google Scholar
• LINDEKE, B., PAULSEN, U. and ANDERSON, E., 1979, Cytochrome P-455 complex formation in the metabolism of phenylalltylamines-IV. Spectral evidences for metabolic conversion of metham-phetamine to N-hydroxyamphetamine. Biochemical Pharmacology, 28, 3629–3635.
   PubMed Web of Science ®Google Scholar
• LOWRY, 0. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   Google Scholar
• MAHNKE, A., STROTKAMP, D., Roos, P. H., HANSTEN, W. G., CHABOT, G. G. and NEF, P., 1997, Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver. Archives of Biochemistry and Biophysics, 337, 62–68.
   PubMed Web of Science ®Google Scholar
• MANSUY, D., ROUER, E., BACOT, C., GANS, P., CHOTTARD J. C. and LEROUX, J. P., 1978, Interaction of aliphatic N-hydroxylamines with microsomal cytochrome P450: nature of the different derived complexes and inhibitory effects on monoxygenases activities. Biochemical Pharmacology, 27, 1229–1237.
   Google Scholar
• McNEIL, C. M. and MURRAY, M., 1996, Inhibition of microsomal cytochromes P450 in rat liver by the tricyclic antidepressant drug desipramine and its primary oxidized metabolites. Biochemical Pharmacology, 51, 15–20.
   PubMed Web of Science ®Google Scholar
• MURRAY, M., 1988, Complexation of cytochrome P450 isozymes in hepatic microsomes from SKF-525-A-induced rats. Archives of Biochemistry and Biophysics, 262, 381–388.
   PubMed Web of Science ®Google Scholar
• MURRAY, M., 1992, Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. Molecular Pharmacology, 42, 931–938.
   PubMed Web of Science ®Google Scholar
• MURRAY, M. and BUTLER, A. M., 1996, Enhanced inhibition of microsomal cytochrome P450 3A2 in rat liver during diltiazem biotransformation. Journal of Pharmacology and Experimental Therapeutics, 279, 1447–1452.
   PubMedGoogle Scholar
• MURRAY, M. and FIELD, S. L., 1992, Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants. Biochemical Pharmacology, 43, 2065–2071.
   PubMed Web of Science ®Google Scholar
• MURRAY, M., ZALUZNY, L. and FARRELL, G. C., 1986, Drug metabolism in cirrhosis: Selective changes in cytochrome P-450 isozymes in the choline-deficient rat model. Biochemical Pharmacology, 35, 1817–1824.
   PubMed Web of Science ®Google Scholar
• MURRAY, M. and REIDY, G. F., 1990, Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacological Reviews, 42, 85–101.
   PubMed Web of Science ®Google Scholar
• MURRAY, M., HUDSON, A. M. and YASSA, V., 1992, Hepatic microsomal metabolism of the anthelmintic benzirnidazole fenbendazole: Enhanced inhibition of cytochrome P450 reactions by oxidized metabolites of the drug. Chemical Research in Toxicology, 5, 60–66.
   PubMed Web of Science ®Google Scholar
• MURRAY, M., WILKINSON, C. F. and DUBE, C. E., 1983, Effects of dihydrosafrole on cytochromes P-450 and drug oxidation in hepatic microsomes from control and induced rats. Toxicology and Applied Pharmacology, 68, 66–76.
   PubMed Web of Science ®Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370–2378.
   PubMed Web of Science ®Google Scholar
• PIEPHO, R. W., CULBERTSON, V. L. and RHODES, R. S., 1987, Drug interactions with the calcium-entry blockers. Circulation, 75, V–181–194.
   Google Scholar
• REIDY, G. F., MEHTA I. and MURRAY, M., 1989, Inhibition of oxidative drug metabolism by orphenadrine : In vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Molecular Pharmacology, 35, 736–743.
   Google Scholar
• REIN, H. and RISTAU, 0., 1978, The importance of the high spin/low spin equilibrium existing in cytochrome P-450 for the enzymatic mechanism. Pharmazie, 33, 325–328.
   Google Scholar
• REIN, H., RISTAU, 0., MissELmirrz, R., BUDER, E. and RUCKPAUL, K., 1979, The importance of the spin equilibrium in cytochrome P-450 for the reduction rate of the heme iron. Acta Biologica et Medico Germanica, 38, 187–199.
   Google Scholar
• RENTON, K. W., 1985, Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochemical Pharmacology, 34, 2549–2553.
   PubMedGoogle Scholar
• SIRMANS, S. M., PIEPER, J. A., LALONDE, R. L., SMITH, D. G. and SELF, T. H., 1988, Effect of calcium channel blockers on theophylline disposition. Clinical Pharmacology and Therapeutics, 44, 29-34, 1988.
   Google Scholar
• TOWBIN, H., STAEHELIN, T. and GORDON, J., 1979, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proceedings of the National Academy of Sciences, USA, 76, 4350–4354.
   PubMed Web of Science ®Google Scholar
• WAXMAN, D. J., DANNAN, G. A. and GUENGERICH, F. P., 1985, Regulation of rat hepatic cytochrome P-450: Age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes. Biochemistry, 24, 4409–4417.
   PubMed Web of Science ®Google Scholar
• WAXMAN, D. J., Ko, A. and WALSH, C., 1983, Regioselectivity and stereoselectivity of androgen hydroxylations catalysed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. Journal of Biological Chemistry, 258, 11937–11947.
   PubMed Web of Science ®Google Scholar
• WONG, Y. Y., LUDDEN, T. M. and BELL, R. D., 1982, Effect of erythromycin on carbamazepine kinetics. Clinical Pharmacology and Therapeutics, 33, 460-464, 1982.
   Google Scholar
• WRIGHTON, S. A., BRIAN, W. R., SARI, M.-A., IWASAKI, M., GUENGERICH, F. P., RAUCY, J. L., MOLOWA D. T. and VANDENBRANDEN, M., 1990, Studies on the expression and metabolic capabilities of human liver cytochrome P45011IA5 (HLp3). Molecular Pharmacology, 38, 207–213.
   Google Scholar